Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects
elderly individuals. Increase in incidence rates in the past decades has been attributed to …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-
lymphocyte–associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer …

Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease
provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and …

Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus
followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated …

Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating
autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have …

Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease
that mainly affects the elderly. Typical clinical features include the widespread blisters, often …

Background Inhibitors of dipeptidyl peptidase (DPP)‐IV have been suspected in the onset of
bullous pemphigoid for several years now. However, comparative studies assessing the link …

Bullous pemphigoid (BP) is an autoimmune blistering disease which carries a significant
mortality and morbidity. While historically BP has been characterized as an IgG driven …

Lichen planus pemphigoides (LPP) is a very rare autoimmune sub-epidermal blistering
disease associated with lichenoid skin changes. Initially thought to be a mere variant of …